CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Atavistik Bio Enhances Atavistic's AMPS Platform through Collaboration with Plex Research

Atavistik Bio Enhances Atavistic's...

The Two Key Trends Of AI In Biotechnology

The Two Key Trends Of AI In...

Compound K', Is Fast Absorbing And Has A Higher Immune-Boosting Effect Than Ginseng

Compound K', Is Fast Absorbing And...

Informa Pharma Intelligence announces the launch of its Citeline Connect

Informa Pharma Intelligence announces...

Industry Giants Say Covid-19 Offers A 'Significant Opportunity' To Fast-Track Cancer Eradication

Industry Giants Say Covid-19 Offers A...

How Does Biotechnology Help the World

How Does Biotechnology Help the World

Pharma and Biotech are Looking to Cloud and AI to Expediate Drug Discovery

Pharma and Biotech are Looking to...

Advantages of Biotech Partnership

Advantages of Biotech Partnership

Atavistik Bio Enhances Atavistic's AMPS Platform through Collaboration with Plex Research

Atavistik Bio Enhances Atavistic's...

The Two Key Trends Of AI In Biotechnology

The Two Key Trends Of AI In...

Compound K', Is Fast Absorbing And Has A Higher Immune-Boosting Effect Than Ginseng

Compound K', Is Fast Absorbing And...

Informa Pharma Intelligence announces the launch of its Citeline Connect

Informa Pharma Intelligence announces...

Industry Giants Say Covid-19 Offers A 'Significant Opportunity' To Fast-Track Cancer Eradication

Industry Giants Say Covid-19 Offers A...

How Does Biotechnology Help the World

How Does Biotechnology Help the World

Pharma and Biotech are Looking to Cloud and AI to Expediate Drug Discovery

Pharma and Biotech are Looking to...

Advantages of Biotech Partnership

Advantages of Biotech Partnership

Celsion Corporation Introduces a Wholly-Owned Subsidiary to Develop ThermoDox

Life Sciences Review Life Sciences Review | Thursday, December 23, 2021
Tweet

Celsion GmbH oversees ongoing and future cancer research with ThermoDox®.


FREMONT, CA: Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, declares that its newly formed wholly-owned subsidiary, Celsion GmbH, will oversee all ongoing and future investigator-sponsored development of ThermoDox®, the Company's proprietary heat-activated liposomal encapsulation of doxorubicin. Andreas Voss, M.D., a renowned oncologist, joins Managing Director of Celsion GmbH. Later this year, he will resign from Celsion's board of directors to lead the subsidiary based in Zug, Switzerland.


Celsion's management now focuses exclusively on GEN-1, DNA-mediated IL-12 immunotherapy in Phase I/II development for the treatment of advanced ovarian cancer, and PLACCINE", its nucleic acid vaccine platform. Celsions' ongoing investment in ThermoDox® will be limited to clinical drug supply and modest financial support.


ThermoDox® is currently being developed on an investigator-sponsored basis for a variety of cancer indications, including:


A Phase I study led by the University Medical Center Utrecht in the Netherlands to determine the safety, tolerability, and feasibility of ThermoDox® in combination with Magnetic Resonance Guided High Intensity Focused Ultrasound hyperthermia and cyclophosphamide therapy for the local treatment of metastatic breast cancer's primary tumor.


A Phase I study led by Oxford University in the United Kingdom will evaluate the intravenous administration of ThermoDox® in combination with High Intensity Focused Ultrasound in patients with pancreatic cancer.


The National Institutes of Health is conducting a clinical trial to evaluate ThermoDox® in combination with the chemotherapy drug mitomycin in patients with bladder cancer.


Commenting on his new role in leading Celsion GmbH, Dr. Voss says, “I am excited to spearhead this effort and to work with investigators around the world who are interested in pursuing further clinical development of ThermoDox®. Building upon encouraging preclinical results in several cancer indications, we have been fielding numerous requests from investigators to conduct their own studies. We know that doxorubicin is one of the most active cytotoxic drugs with no known specific resistance mechanism. Furthermore, the ability of ThermoDox® to deliver high doses into tumor tissue is proven and its mechanism of action is well understood. Celsion GmbHs long-term objective is to seek partnerships that will maximize the potential of ThermoDox®, ultimately providing value to the parent company.”


Michael H. Tardugno, Celsions chairman, president, and chief executive officer, says, “Despite the bitter disappointment and surprise with our Phase III OPTIMA study of ThermoDox® in primary liver cancer, many investigators are undaunted by various anomalies related to that data and see value in the drugs continued study. We owe patients and the scientific community the opportunity to investigate ThermoDox® while removing the financial obligation from our stockholders. Celsion is now solely focused on the significant opportunity we face with GEN-1 and PLACCINE in advanced ovarian cancer and SARS-CoV-2 vaccines, respectively. I am delighted that Celsion GmbH is in the experienced hands of Dr. Voss, who will pursue other collaborations and partnerships with the intent to monetize this asset.”


Weekly Brief

loading
Top 10 Biotech Startups in APAC - 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Antibodies: Immunoglobulin Isotypes

Life Science Consulting Services Trends

Rani Therapeutics and Celltrion Partner to Develop Oral Monoclonal Antibodies

ProPhase Labs Acquires BE-Smart Esophageal Pre-Cancer Screening Test

The Influence of Pharmaceutical Distributors on U.S. Drug Expenditures

Tips to Improve Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/celsion-corporation-introduces-a-whollyowned-subsidiary-to-develop-thermodox-nwid-438.html